Recently, Australia has approved the drug Lecanemab for treating early-stage Alzheimer's disease. This approval marks a significant milestone in Alzheimer's treatment, as it targets the underlying causes of the disease rather than merely alleviating its symptoms.
Type: Monoclonal antibody drug
Purpose: Designed to treat the early stages of Alzheimer’s disease, Lecanemab works by slowing down disease progression.
Target: It specifically targets amyloid proteins in the brain, which are believed to play a central role in the development of Alzheimer’s.
Goal: Unlike traditional treatments that address symptoms, Lecanemab is aimed at tackling the causes of Alzheimer's disease.
Mechanism: Lecanemab uses antibodies to identify amyloid proteins in the brain, which are toxic to brain cells. The drug works with the brain's immune cells to clear the build-up of amyloid proteins.
Amyloid plaques are a hallmark of Alzheimer’s disease. These plaques are thought to disrupt communication between brain cells, eventually causing them to die.
Delivery: Lecanemab is administered intravenously, meaning it is given directly into the vein through a drip.
Recent clinical trials have shown promising results, with a 27% reduction in disease progression among patients receiving the drug. This is a significant step forward, especially considering that Alzheimer’s disease has long been considered incurable.
High Cost: One of the main issues with Lecanemab is its high cost, which could limit its accessibility to many patients, particularly in low-income regions.
Side Effects: There are concerns about the potential side effects of the drug, particularly brain swelling. This could raise safety concerns, especially for long-term use.
Despite these issues, the drug represents a new frontier in the treatment of Alzheimer's, targeting the disease's underlying pathology rather than just managing symptoms.
Alzheimer's Disease is a brain disorder that slowly deteriorates memory, thinking skills, and, eventually, the ability to carry out the simplest tasks.
It is the most common cause of dementia, which refers to memory loss and cognitive impairments that interfere with daily life.
Prevalence: Alzheimer’s accounts for 60-80% of all dementia cases.
Impact on the Brain: The disease primarily affects parts of the brain that control thought, memory, and language.
Age Factor: Typically affects those aged 65 years or older, though 10% of cases occur in those younger than 65.
The approval of Lecanemab in Australia is a major development in the fight against Alzheimer's disease. While the drug’s effectiveness is promising, especially in slowing disease progression by targeting amyloid plaques, challenges such as cost and potential side effects remain. Nevertheless, Lecanemab provides a hopeful new approach for early-stage Alzheimer's treatment, marking a shift from symptom management to targeting the disease's root causes.
We provide offline, online and recorded lectures in the same amount.
Every aspirant is unique and the mentoring is customised according to the strengths and weaknesses of the aspirant.
In every Lecture. Director Sir will provide conceptual understanding with around 800 Mindmaps.
We provide you the best and Comprehensive content which comes directly or indirectly in UPSC Exam.
If you haven’t created your account yet, please Login HERE !
We provide offline, online and recorded lectures in the same amount.
Every aspirant is unique and the mentoring is customised according to the strengths and weaknesses of the aspirant.
In every Lecture. Director Sir will provide conceptual understanding with around 800 Mindmaps.
We provide you the best and Comprehensive content which comes directly or indirectly in UPSC Exam.
Offline/Online Class